Novo Nordisk Partners With Anthropic to Speed Up Drug Discovery Using Claude AI

Novo Nordisk has partnered with Anthropic to apply the AI company’s Claude models toward accelerating the discovery and development of new medicines, the two companies announced Wednesday. The deal gives the Danish pharmaceutical giant, best known for GLP-1 drugs Ozempic and Wegovy, access to Claude Science, Anthropic’s dedicated scientific research workbench, alongside its broader frontier AI models.

What the Partnership Actually Covers

As an initial step, Novo said it will test Claude Science on specific research and development workflows, focusing on scientific problems where the two companies’ combined capabilities are expected to have the greatest impact. The companies described the collaboration as addressing drug discovery challenges identified directly by Novo’s scientists and computational teams, with the goal of building targeted solutions for particular scientific workflows rather than a single, one-size-fits-all tool.

Beyond drug discovery itself, Novo will also use Anthropic’s frontier models to strengthen AI-driven software development across the company, something Novo describes as a key enabler for scaling AI use more broadly across its organization, beyond R&D alone.

Built-In Guardrails: Data Governance and Human Oversight

Novo said the arrangement incorporates data governance protocols and human oversight requirements designed to keep AI use consistent with the company’s compliance standards, language that reflects the heavily regulated environment pharmaceutical companies operate in, where AI-generated research findings ultimately still need to satisfy regulators like the FDA and EMA before any drug reaches patients.

Novo Isn’t New to Claude

This isn’t Novo’s first use of Anthropic’s technology. According to an Anthropic case study describing the drugmaker’s existing deployment, Novo previously built NovoScribe, an AI-powered documentation platform developed using Claude Code on Amazon Bedrock and MongoDB Atlas. The platform pairs retrieval-augmented generation with domain-expert-approved text and case-specific variables to produce regulatory documentation. Anthropic reports that the time spent producing clinical study documentation fell from more than ten weeks to roughly ten minutes using the system, and that resources needed to create device verification protocols dropped by 95 percent, figures drawn from Anthropic’s own case study rather than independently verified third-party results.

Inside Claude Science: What the Workbench Actually Does

Claude Science, the specific tool at the center of this new partnership, functions as a scientific research workbench connected to more than 60 scientific databases, with prebuilt toolkits spanning genomics, proteomics, structural biology, and cheminformatics. It’s built around a primary AI agent capable of spawning specialized sub-agents to divide up complex research workloads, paired with a dedicated reviewer agent that audits citations and calculations before any output reaches a researcher for review, a structure aimed at reducing the kind of fabricated or unverifiable claims that have dogged general-purpose AI tools when applied to scientific work.

Part of a Broader AI Arms Race in Drug Discovery

The Novo-Anthropic deal extends a rapidly growing pattern of AI partnerships across the pharmaceutical industry. It follows an earlier arrangement Anthropic struck with Bristol Myers Squibb in May 2026, giving that drugmaker’s workforce access to Claude across research, clinical development, manufacturing, and commercial functions. Novo itself has been active on multiple AI fronts recently, having also struck a deal with OpenAI earlier this year and established a dedicated AI innovation hub with Amazon Web Services. The Novo Nordisk Foundation separately partnered with Nvidia and Denmark’s Export and Investment Fund in 2024 to build the Danish Centre for AI Innovation, home to Gefion, Denmark’s first AI-ready supercomputer.

Rival drugmaker Eli Lilly has pursued a similar strategy from a different angle, announcing a joint AI drug-discovery lab with Nvidia in January, backed by up to $1 billion in committed investment over five years. That kind of parallel investment across the sector’s two largest GLP-1 competitors suggests AI-accelerated drug discovery is increasingly viewed as a competitive necessity rather than an experimental side project. This intensifying reliance on AI for scientific discovery lines up with a broader trend across healthcare’s AI adoption more broadly, where pharmaceutical and biotechnology applications represent one of the fastest-growing corners of the wider AI-in-healthcare market.

Why This Matters for Novo’s Pipeline

The timing isn’t incidental. Novo is currently working to build out its next generation of obesity and diabetes treatments as it faces intensifying competition from Eli Lilly’s own pipeline, and the company separately confirmed Wednesday it will present 44 abstracts at a European diabetes symposium later this month. Novo CEO Mike Doustdar framed the Anthropic partnership as central to that broader push, saying it would help the company increase R&D productivity and compress the path from research to marketed product.

Anthropic CEO Dario Amodei, for his part, characterized the potential impact in sweeping terms, describing AI’s growing capability as holding the potential to compress a century’s worth of biological and medical breakthroughs into a single decade, a framing echoed elsewhere in Anthropic’s own commentary on AI’s role in drug discovery and precision medicine more broadly, where AI companies and healthcare executives alike have increasingly argued that healthcare represents AI’s single largest untapped opportunity.

What Comes Next

For now, the partnership remains in an early testing phase, with Novo evaluating Claude Science against specific R&D workflows rather than deploying it company-wide. Whether that testing translates into faster drug approvals or genuinely new scientific discoveries, as opposed to incremental efficiency gains in documentation and software development, will likely take months or years to become clear, the same uncertainty that shadows nearly every AI-pharma partnership announced across the industry so far.